Saffron for Anxiety

Verdict: Promising but unsettled: modest anxiety relief

Standardized saffron extract (about 28-100 mg/day) shows a consistent signal for reducing anxiety symptoms in short trials, but the evidence is still preliminary, the studies are small, and it should not replace established treatment. It is not approved by regulators as an anxiety remedy.

B 🟡 B Preliminary Evidence Published with Warning

🔬Why this grade7-layer evidence engine

This earns a Preliminary (Grade B) rating because the direction of evidence is consistent but its strength is limited. Two meta-analyses both found a statistically significant drop in anxiety scores versus placebo: PMID 31135916 (n=1006) reported a large pooled effect (SMD -0.95, 95% CI -1.45 to -0.45), and PMID 31987241 (n=945) found a WMD of -2.19 points (95% CI -3.83 to -0.55). Three double-blind RCTs (PMID 27101556, 28735826) reinforced this on HAM-A, BAI, and DASS-21 scales.

Several caveats keep it out of the top tier. Both meta-analyses showed very high heterogeneity (I-squared around 80%), so the headline effect sizes are imprecise. Most trials were small (under 100 participants) and short (4-8 weeks), populations were mixed (subclinical, comorbid depression, GAD), and sites were mostly Iranian. Notably, the youth trial (PMID 29510352) was mixed: teens self-reported improvement but parent-rated outcomes did not differ, and the key standardized-extract trials were industry-funded.

Regulators and clinics are cautious. The US FDA lists saffron only as a food color/flavoring with no approved health claim, and the EU EFSA explicitly rejected mood claims, stating 'a cause and effect relationship has not been established.' Cleveland Clinic notes saffron may ease anxiety but stresses the studies are small and that it should not replace prescribed medication. Hence: a real but unproven aid, published with a warning.

⚖️

Scoring transparency

All scores computed by a 7-layer evidence engine — fully auditable
Raw score 0.68
D
C
B
A
S
← counter-evidence / ineffectiveeffective / strong evidence →
Final grade
B · Published with Warning
Confidence
77%
Broadly consistent
Evidence level
E2
Multiple high-quality MAs (≥2 independent, consistent)

How strongly each layer supports this effect

lower = less supportive
L1 ExamineGlobal benchmark
0.50
L5 Clinical bodiesAuthoritative stance
0.60
L3 MechanismPlausibility
0.65
L11 AI re-checkIndependent read
0.65
L2 PubMedPrimary literature
0.85
Against Mixed Supports
View the full decision path (audit trail)
  1. compute_raw_score — 加權公式: L2×0.30 + L3×0.25 + L5×0.25 + L11×0.10 + L1×0.10 = 0.683
  2. tier_from_score — 依分數區間映射至 tier letter
  3. apply_hec_rules — 高品質 SR/MA 顯示 positive (3 篇 > 0 negative)
  4. tier_strict_requirement_check — Tier 條件達標,未降階
  5. detect_disputes — 偵測到 0 個 hard + 0 個 soft dispute
  6. decide_status — 依 tier + dispute 結果決定 status

📄PubMed studies (6)L2 · primary research & systematic reviews

Effect of saffron supplementation on symptoms of depression and anxiety: a systematic review and meta-analysis
PMID: 31135916 2019 統合分析 n = 1,006
Finding: Across reviewed RCTs, saffron showed consistent anxiolytic effect signal at 30-100 mg/day with HAM-A reduction; SR concluded mental health benefits plausible but RCTs small and short
🟠 Limited quality
View on PubMed
The effects of saffron (Crocus sativus L.) on mental health parameters and C-reactive protein: A meta-analysis of randomized clinical trials
PMID: 31987241 2021 統合分析 n = 945
Finding: Saffron significantly improved anxiety scores compared with placebo (WMD -2.19, 95% CI -3.83 to -0.55; p=0.009); also reduced depression and improved BDNF; high heterogeneity
Effect size: [object Object]
View on PubMed
A double-blind, randomized and placebo-controlled trial of Saffron (Crocus sativus L.) in the treatment of anxiety and depression
PMID: 27101556 2016 RCT (double-blind) n = 60
Finding: Saffron group showed significantly greater reductions in HAM-A and BAI scores vs placebo at week 6 (p<0.001); no serious adverse events
Academic
View on PubMed
Affron, a standardised extract from saffron (Crocus sativus L.) for the treatment of youth anxiety and depressive symptoms: A randomised, double-blind, placebo-controlled study
PMID: 29510352 2018 RCT (double-blind) n = 80
Finding: Saffron-treated youth (12-16y) showed significantly greater improvement in internalizing/anxiety subscale per youth self-report vs placebo over 8 weeks; parent-rated outcomes did not significantly differ
⚠️ Industry-funded
View on PubMed
affron® a novel saffron extract (Crocus sativus L.) improves mood in healthy adults over 4 weeks in a double-blind, parallel, randomized, placebo-controlled clinical trial
PMID: 28735826 2017 RCT (double-blind) n = 56
Finding: Saffron group showed significant reductions in DASS-21 anxiety (p<0.05) and depression subscales vs placebo at 4 weeks; effect size moderate
⚠️ Industry-funded
View on PubMed
Effect of saffron supplementation on symptoms of depression and anxiety: a systematic review and meta-analysis
PMID: 31135916 2019 系統性回顧
Finding: Across reviewed RCTs, saffron showed consistent anxiolytic effect signal at 30-100 mg/day with HAM-A reduction; SR concluded mental health benefits plausible but RCTs small and short
🟠 Limited quality
View on PubMed

🏛️Regulatory & authoritative positionsL4/L5 · FDA / EMA / NIH ODS / Cochrane / Mayo …

L4a US FDA
Cautious
Saffron (Crocus sativus L.); CAS 977051-90-3; 21 CFR 73.500, 182.10; COLOR OR COLORING ADJUNCT, FLAVOR ENHANCER, FLAVORING AGENT OR ADJUVANT. source↗
L4b EU EFSA
Against
a cause and effect relationship has not been established source↗
L4d TW TFDA / 衛福部
Cautious
番紅花(Crocus sativus L.)之柱頭可供食品使用 source↗
L5c Cleveland Clinic
Supportive
Saffron may help ease symptoms of anxiety and depression source↗
PMID 100% verifiedevery citation checked via NCBI Entrez
🔬6 PubMed studiesindependently re-checked by multiple sub-agents
engine_version: v1.0 claim_id: CLM-COND-anxiety-INT-saffron-001 繁體中文版 →